Whilst there was only a limited pool of relatively small trials and a number of different compounds , we found that collectively , both AChEIs ( donepezil and rivastigmine ) and stimulants ( methylpheni date , modafinil , l‐amphetamine sulfate and lisdexamfetamine dimesylate ) offered no significant benefits over placebo on measures of processing speed , working memory , verbal fluency , verbal memory , visuospatial memory or executive functioning
HighlightsCognitive deficits are present in up to 70 % of people with multiple sclerosis (MS).There are no approved treatments for these difficulties .
We examined whether adjunctive pharmacotherapies can improve cognition in MS.Acetylcholinesterase inhibitors offered no significant benefits over placebo .
Stimulant‐based medications offered no significant benefits over placebo .
& NA ; We sought to examine the effectiveness of acetylcholinesterase inhibitors ( AChEIs ) and stimulant‐based medications for improving cognitive performance in patients with multiple sclerosis ( MS ) .
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients
To examine the efficacy and toxicity of oral 3,4 diaminopyridine ( DAP ) in dosages up to 100 mg/day , 36 patients with multiple sclerosis ( MS ) enrolled in a r and omized , double-blind , placebo-controlled , crossover trial . The primary outcome measure was improvement of a prospect ively defined neurologic deficit , which was leg weakness in 34 patients . Secondary outcome measures included the patient 's subjective response , scored manual motor testing ( MMT ) of leg strength , scored leg strength from videotaped motor testing ( VMT ) , quadriceps and hamstrings strength ( QMT ) measured by isometric dynamometry , neuropsychological testing ( NPT ) , ambulation index ( AI ) , and Exp and ed Disability Status Scale ( EDSS ) score . Paresthesias and abdominal pain were common and were dose limiting in eight patients . Three patients had episodes of confusion , and one patient had a seizure while on DAP . Eight patients withdrew from the study , leaving 28 evaluable patients for the efficacy analysis . The prospect ively defined neurologic deficit improved in 24 patients -22 on DAP and 2 on placebo ( p = 0.0005 ) . All improvements were in leg weakness . Subjective response and measures of leg strength and function ( MMT , VMT , QMT , and AI ) improved on DAP compared with placebo . Neither NPT nor EDSS scores improved . DAP treatment can induce improvements in leg strength in MS patients , but toxicity is limiting in many patients . NEUROLOGY 1996;47 : 1457 -
Whilst there was only a limited pool of relatively small trials and a number of different compounds , we found that collectively , both AChEIs ( donepezil and rivastigmine ) and stimulants ( methylpheni date , modafinil , l‐amphetamine sulfate and lisdexamfetamine dimesylate ) offered no significant benefits over placebo on measures of processing speed , working memory , verbal fluency , verbal memory , visuospatial memory or executive functioning
HighlightsCognitive deficits are present in up to 70 % of people with multiple sclerosis (MS).There are no approved treatments for these difficulties .
We examined whether adjunctive pharmacotherapies can improve cognition in MS.Acetylcholinesterase inhibitors offered no significant benefits over placebo .
Stimulant‐based medications offered no significant benefits over placebo .
& NA ; We sought to examine the effectiveness of acetylcholinesterase inhibitors ( AChEIs ) and stimulant‐based medications for improving cognitive performance in patients with multiple sclerosis ( MS ) .